Russia's economy is now so militarized, it may keep expanding its army even after the Ukraine war
Military spending is driving Russia's economy, sustaining it despite Western sanctions.
Russia's militarized economy is supporting political and economic stakeholders, deterring cutbacks.
Russia's war machine has become such an integral part of its economic engine that its military industry is likely to keep expanding even after the fighting in Ukraine ends, according to a report from the Center for Strategic and International Studies.
"The end of hostilities will not lead to a radical cut-off of military investment," wrote CSIS analysts in a report published on Thursday.
Now in its fourth year, Russia's war with Ukraine continues even as Russian President Vladimir Putin's administration weathers sweeping Western sanctions. And while cracks are starting to show, the Russian economy may still be able to sustain the war effort for several more years, the report said.
Defense spending is set to hit a post-Soviet record of 6.3% of GDP in 2025 and could climb even higher despite mounting signs of economic slowdown or recession.
"Russia's economy appears sustainable for the next few years," the CSIS analysts wrote. They forecast that the Kremlin could maintain its war of attrition through at least 2027.
'Russia could be preparing for some kind of future confrontation with NATO'
The CSIS report comes amid renewed scrutiny of Russia's economy.
Manufacturing activity contracted last month, and employment has suffered. GDP growth slowed to 1.4% in the first quarter, down sharply from 4.5% in the previous quarter.
Still, Russia has defied expectations thanks to its growing military-industrial complex.
"Having become the most sanctioned country in the world, it has managed to maneuver around many economic constraints, keeping revenues from energy sales high and its budget balanced, investing in the military and defense industry, ramping up domestic production of weapons and equipment, and boosting economic growth," wrote the think tank analysts.
Crucially, the militarized economy has built a broad base of political and economic stakeholders — from elites to ordinary workers — who benefit from continued conflict. That makes any significant drawdown in military activity politically and economically unlikely.
Even if a ceasefire is reached, Russia may still be able to rebuild and expand its armed forces over the next decade.
"Russia's war-induced socioeconomic changes have been so significant that the process of societal militarization is unlikely to stop even if the war in Ukraine were to end," wrote the CSIS analysts.
The Kremlin's strategic posture hasn't softened either. CSIS suggests Russia is preparing for a long-term confrontation with NATO, using the war to modernize its forces and test Western resolve.
Beyond conventional arms, Russia has ramped up hybrid warfare, including cyberattacks, disinformation, sabotage, political meddling, and strikes on critical infrastructure. These tools allow Moscow to operate aggressively across multiple fronts.
"Despite being inferior to NATO in terms of its conventional capabilities, today's Russia represents a bigger challenge to European security than it did at the start of 2022," the CSIS analysts wrote.
The Kremlin is learning from past failures, adapting quickly, and growing more confident in what it sees as a West unwilling to stop it.
"Moscow's ongoing large-scale military reforms signal that Russia could be preparing for some kind of future confrontation with NATO within roughly the next decade—including even a large-scale conventional war," they wrote.
Read the original article on Business Insider
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Washington Post
13 minutes ago
- Washington Post
What's known and not yet known about the Justice Department's scrutiny of Trump-Russia probe origins
WASHINGTON — News that Attorney General Pam Bondi is moving to criminally investigate the Obama-era origins of the Trump-Russia investigation means that one of the most studied, and politically polarizing, chapters of modern American history will be under the microscope yet again. Here's a look at what's known and not yet known about the latest Justice Department revelation:
Yahoo
29 minutes ago
- Yahoo
ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025
LAUSANNE, Switzerland, Aug. 5, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Tuesday, August 12, 2025, at 8:30 a.m. EDT to report financial results for the second quarter of 2025 and provide operational updates. To access the conference call, please register here. The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. It is recommended that you join 10 minutes before the event, though you may pre-register at any time. A live webcast of the call will be available under "Events and Presentations" in the Investors section of the ADC Therapeutics website at The archived webcast will be available for 30 days following the call. About ADC Therapeutics ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA and a PSMA-targeting ADC. ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics is leveraging its expertise to advance IND-enabling activities for a next-generation PSMA-targeting ADC which utilizes a differentiated exatecan-based payload with a novel hydrophilic linker. Headquartered in Lausanne (Biopôle), Switzerland, with operations in London and New Jersey, ADC Therapeutics is focused on driving innovation in ADC development with specialized capabilities from clinical to manufacturing and commercialization. Learn more at and follow us on LinkedIn. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as "may", "will", "should", "would", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "future", "continue", or "appear" or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the success of the Company's strategic restructuring plan; changes in estimated costs associated with the restructuring plan including the workforce reduction and planned closure of the UK facility; the expected cash runway into 2028 which assumes use of minimum liquidity amount required to be maintained under its loan agreement covenants; whether future LOTIS-7 clinical trial results will be consistent with or different from the LOTIS-7 data presented at EHA and ICML and future compendia and regulatory strategy and opportunity; the timing of the PFS events for LOTIS-5 and the results of the trial and full FDA approval; the Company's ability to grow ZYNLONTA® revenue in the United States and potential peak revenue; the ability of our partners to commercialize ZYNLONTA® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain regulatory approval for ZYNLONTA® in foreign jurisdictions; the timing and results of the Company's or its partners' research and development projects or clinical trials including LOTIS 5 and 7, as well as early pre-clinical research for our exatecan-based ADC targeting PSMA; the timing and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company's products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company's indebtedness, including Healthcare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company's activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; and the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K and in the Company's other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. CONTACTS:Investors and MediaNicole RileyADC 862-926-9040 View original content to download multimedia: SOURCE ADC Therapeutics SA Sign in to access your portfolio
Yahoo
29 minutes ago
- Yahoo
Opera to Announce Second Quarter 2025 Financial Results on August 19, 2025
OSLO, Norway, Aug. 5, 2025 /PRNewswire/ -- Opera Limited (NASDAQ: OPRA), one of the world's major browser developers and a leading internet consumer brand, announced today that the company's second quarter 2025 financial results will be released before the market opens on Tuesday, August 19, 2025. The earnings release will be available on our investor relations website at Management will host a conference call to discuss the second quarter 2025 financial results on the same day at 8:00 a.m. ET. Listeners may access the call by dialing the following numbers: United States: +1 800-225-9448Norway: +47 80-01-3780International: +1 203-518-9708 Confirmation Code: OPRAQ225 A live webcast of the conference call can be accessed at About OperaOpera is a user-centric and innovative software company focused on enabling the best possible internet browsing experience across all devices. Hundreds of millions use the Opera web browsers for their unique and secure features on their mobile phones and desktop computers. Founded in 1995, and headquartered in Oslo, Norway, Opera is a public company listed on the Nasdaq stock exchange under the ticker symbol "OPRA". Download the Opera web browser and access other Opera products from Learn more about Opera at View original content to download multimedia: SOURCE Opera Limited Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data